Details
Stereochemistry | ACHIRAL |
Molecular Formula | C20H26N2O4 |
Molecular Weight | 358.4314 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
COC1=C(OC)C=C(C=C1)C(=O)NCC2=CC=C(OCCN(C)C)C=C2
InChI
InChIKey=QQQIECGTIMUVDS-UHFFFAOYSA-N
InChI=1S/C20H26N2O4/c1-22(2)11-12-26-17-8-5-15(6-9-17)14-21-20(23)16-7-10-18(24-3)19(13-16)25-4/h5-10,13H,11-12,14H2,1-4H3,(H,21,23)
DescriptionSources: https://www.rlsnet.ru/tn_index_id_36285.htmCurator's Comment: description was created based on several sources, including
http://www.meppo.com/pdf/drugs/2845-GANATON-1415104080.pdf
Sources: https://www.rlsnet.ru/tn_index_id_36285.htm
Curator's Comment: description was created based on several sources, including
http://www.meppo.com/pdf/drugs/2845-GANATON-1415104080.pdf
Itopride is a dopamine D2 receptor antagonist and inhibitor of acetylcholinesterase. It is indicated in the for the treatment of gastrointestinal symptoms caused by reduced gastrointestinal motility, such as functional non-ulcer dyspepsia (chronic gastritis), gastric fullness, rapid satiation, pain or discomfort in the upper abdomen, anorexia, heartburn, nausea, and vomiting. The drug is not approved in the USA or UK but is available in Japan and Western European countries.
CNS Activity
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: P22303|||Q53F46 Gene ID: 43.0 Gene Symbol: ACHE Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/7869618 |
2.04 µM [IC50] | ||
Target ID: CHEMBL217 Sources: https://www.ncbi.nlm.nih.gov/pubmed/1831229 |
0.16 nM [Kd] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Palliative | GANATON Approved UseGastrointestinal symptoms in chronic gastritis (bloated feeling, upper abdominal pain, anorexia, heartburn, nausea, and vomiting) |
|||
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
PubMed
Title | Date | PubMed |
---|---|---|
The involvement of flavin-containing monooxygenase but not CYP3A4 in metabolism of itopride hydrochloride, a gastroprokinetic agent: comparison with cisapride and mosapride citrate. | 2000 Oct |
|
Quantitation of itopride in human serum by high-performance liquid chromatography with fluorescence detection and its application to a bioequivalence study. | 2005 Apr 25 |
|
How effective is itopride for the treatment of patients with functional dyspepsia? | 2006 Sep |
|
Mirtazapine for severe gastroparesis unresponsive to conventional prokinetic treatment. | 2006 Sep-Oct |
|
Simultaneous determination of rabeprazole sodium and itopride hydrochloride in capsule dosage form by spectrophotometry. | 2007 Feb-2008 Nov |
|
Determination of itopride in human plasma by liquid chromatography coupled to tandem mass spectrometric detection: application to a bioequivalence study. | 2007 Jan 30 |
|
A double-blind, randomized, placebo-controlled trial of itopride (100 and 200 mg three times daily) on gastric motor and sensory function in healthy volunteers. | 2007 Mar |
|
Meta-analysis of the effects of prokinetic agents in patients with functional dyspepsia. | 2007 Mar |
|
Mosapride in gastrointestinal disorders. | 2008 |
|
Itopride and pantoprazole outcomes in diabetic gastroparesis trial (IPOD trial). | 2008 Dec |
|
Prokinetics and fundic relaxants in upper functional GI disorders. | 2008 Dec |
|
Potentiation by cholinesterase inhibitors of cholinergic activity in rat isolated stomach and colon. | 2008 Nov-Dec |
|
Acotiamide hydrochloride (Z-338), a novel prokinetic agent, restores delayed gastric emptying and feeding inhibition induced by restraint stress in rats. | 2008 Sep |
|
Applications of nanomaterials in electrogenerated chemiluminescence biosensors. | 2009 |
|
Effectiveness of prokinetic agents against diseases external to the gastrointestinal tract. | 2009 Apr |
|
Determination of itopride hydrochloride in human plasma by RP-HPLC with fluorescence detection and its use in bioequivalence study. | 2009 Mar |
|
Tardive dyskinesia associated with long-term administration of escitalopram and itopride in major depressive disorder. | 2009 Mar 17 |
|
Pharmacokinetic and bioequivalence study of itopride HCl in healthy volunteers. | 2010 |
|
Idiopathic proximal hemimegacolon in an adult woman. | 2010 Apr |
|
Development and validation of a LC-MS/MS method for the determination of clebopride and its application to a pharmacokinetics study in healthy Chinese volunteers. | 2010 Aug 1 |
|
A Simple RP-HPLC Method for Quantitation of Itopride HCl in Tablet Dosage Form. | 2010 Oct |
|
Effect of reversible ligands on oxime-induced reactivation of sarin- and cyclosarin-inhibited human acetylcholinesterase. | 2015 Feb 3 |
Patents
Sample Use Guides
The usual adult dosage is 150mg of itopride hydrochloride (3 tablets) per oral administration daily in three divided doses before meals. The dose may be reduced according to the patient’s age and symptoms.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/1831229
To study the interaction between itopride and D2 receptors, rat striatum homogenate was used. The striatal homogenate was incubated with [3H]spiperone (at a final concentration of 0.3 nM), 10nM ketanserin and 10M pargyline, and the displacing ligand at a final concentration from 1 pM to 100 uM. Radioactivity was measured using filtration through Whatman GF/B filters and liquid scintillation counting.
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C47792
Created by
admin on Fri Dec 15 16:08:12 GMT 2023 , Edited by admin on Fri Dec 15 16:08:12 GMT 2023
|
||
|
WHO-ATC |
A03FA07
Created by
admin on Fri Dec 15 16:08:12 GMT 2023 , Edited by admin on Fri Dec 15 16:08:12 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
ITOPRIDE
Created by
admin on Fri Dec 15 16:08:12 GMT 2023 , Edited by admin on Fri Dec 15 16:08:12 GMT 2023
|
PRIMARY | |||
|
SUB08352MIG
Created by
admin on Fri Dec 15 16:08:12 GMT 2023 , Edited by admin on Fri Dec 15 16:08:12 GMT 2023
|
PRIMARY | |||
|
6879
Created by
admin on Fri Dec 15 16:08:12 GMT 2023 , Edited by admin on Fri Dec 15 16:08:12 GMT 2023
|
PRIMARY | |||
|
DB04924
Created by
admin on Fri Dec 15 16:08:12 GMT 2023 , Edited by admin on Fri Dec 15 16:08:12 GMT 2023
|
PRIMARY | |||
|
CHEMBL2107457
Created by
admin on Fri Dec 15 16:08:12 GMT 2023 , Edited by admin on Fri Dec 15 16:08:12 GMT 2023
|
PRIMARY | |||
|
759643
Created by
admin on Fri Dec 15 16:08:12 GMT 2023 , Edited by admin on Fri Dec 15 16:08:12 GMT 2023
|
PRIMARY | |||
|
C65991
Created by
admin on Fri Dec 15 16:08:12 GMT 2023 , Edited by admin on Fri Dec 15 16:08:12 GMT 2023
|
PRIMARY | |||
|
DTXSID7048320
Created by
admin on Fri Dec 15 16:08:12 GMT 2023 , Edited by admin on Fri Dec 15 16:08:12 GMT 2023
|
PRIMARY | |||
|
122898-67-3
Created by
admin on Fri Dec 15 16:08:12 GMT 2023 , Edited by admin on Fri Dec 15 16:08:12 GMT 2023
|
PRIMARY | |||
|
1512
Created by
admin on Fri Dec 15 16:08:12 GMT 2023 , Edited by admin on Fri Dec 15 16:08:12 GMT 2023
|
PRIMARY | |||
|
100000082842
Created by
admin on Fri Dec 15 16:08:12 GMT 2023 , Edited by admin on Fri Dec 15 16:08:12 GMT 2023
|
PRIMARY | |||
|
81BMQ80QRL
Created by
admin on Fri Dec 15 16:08:12 GMT 2023 , Edited by admin on Fri Dec 15 16:08:12 GMT 2023
|
PRIMARY | |||
|
m6561
Created by
admin on Fri Dec 15 16:08:12 GMT 2023 , Edited by admin on Fri Dec 15 16:08:12 GMT 2023
|
PRIMARY | Merck Index | ||
|
C102254
Created by
admin on Fri Dec 15 16:08:12 GMT 2023 , Edited by admin on Fri Dec 15 16:08:12 GMT 2023
|
PRIMARY | |||
|
3792
Created by
admin on Fri Dec 15 16:08:12 GMT 2023 , Edited by admin on Fri Dec 15 16:08:12 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
METABOLITE (PARENT)
SALT/SOLVATE (PARENT)